2 tracked fund houses held AARTIPHARM in Aug 2026. ICICI Prudential Mutual Fund exited.
All tracked schemes together held 3.55 lakh shares, 0.39% of equity, worth ₹30.0 cr at the end of Aug 2026.
Index and arbitrage funds held 0.15% of equity; they are left out of the fund-house counts.
Top seller ICICI Prudential Mutual Fund, −0.18% of equity. Index and arbitrage funds hidden.
FPI category I + II, % of total shares · 1 named at 1% or more
FPIs named at 1% or more on 30 Jun 2026: Ntasain Discovery Master Fund 2.16%.
disclosed transactions · equity bought 0 sh, sold 29.64 lakh sh
Latest: RAJENDRA VALLABHAJI GOGRI (Promoter), Sell 3.89 lakh Equity worth ₹31,82,77,534, 22 Sep 2026, Market Sale.
of promoter holding · 4.75% of total shares
Promoters had pledged 43.07 lakh of their 3.89 cr shares on 30 Jun 2026; 43.07 lakh encumbered in all (pledge, NDU and other).
percentile 60 of 30 days collected
45 shares, under 0.01% of equity in SLBS open positions at the end of 25 Sep 2026; that day sits at percentile 60 of 30 days collected. No SLBM trades in AARTIPHARM on 25 Sep 2026.
percentile 97 of 29 days collected · ₹71.8 cr financed
8.60 lakh shares, 0.95% of equity in the margin trading book at the end of 24 Sep 2026; that day sits at percentile 97 of 29 days collected.
20-day average 42.0% · percentile 7 of 30 days collected
25.5% of the shares traded on 25 Sep 2026 were delivered, against a 20-day average of 42.0%; that day sits at percentile 7 of 30 days collected.
AARTIPHARM has no F&O contracts in NSE's combined open-interest file, so the F&O ban does not apply. NSE listed AARTIPHARM under no ASM or GSM stage on 25 Sep 2026. Pledge invocations are not collected yet.